BGBIO — Bergenbio ASA Income Statement
0.000.00%
Last trade - 00:00- NOK437.72m
- NOK281.30m
- NOK0.35m
Annual income statement for Bergenbio ASA, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.9 | 0.601 | 0.774 | 0.389 | 0.354 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 213 | 262 | 315 | 306 | 192 |
| Operating Profit | -204 | -261 | -314 | -306 | -192 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -199 | -257 | -309 | -302 | -190 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -199 | -257 | -309 | -302 | -190 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -199 | -257 | -309 | -302 | -190 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -199 | -257 | -309 | -302 | -190 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.387 | -0.394 | -0.404 | -0.391 | -0.133 |
| Dividends per Share |